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EDITORIAL

Newphrologist: The Intensive Care Kidney Specialist

T

he tsunami of CKD has now possibly generated an
even greater wave of acute kidney injury (AKI) that
is sweeping over the world. The causes and frequencies
of AKI differ markedly between developed and developing nations, but the wave of AKI continues to rise.1 The
pre-eminent risk factor for the development of AKI is
CKD, and older patients are at risk for multiple reasons.2
The elderly have less kidney regenerative capacity and
often have chronic medical conditions that render
them more greatly susceptible to kidney insults, such
as ischemic heart disease. Notably, an episode of AKI
may follow several courses: (1) complete recovery, (2)
progressive CKD, (3) worsening of the rate of progression of pre-existent CKD, and (4) evolution to ESRD.2
In fact, the number one reason why a patient is initiated
onto dialytic therapy today in the United States is AKI,
and AKI is common in intensive care units, where nephrologists now spend an ever-increasing amount of
time as consultants.
This issue of Advances in Chronic Kidney Disease underscores a call to action for nephrologists who ply their
tools of trade in intensive care units. The average nephrologist devotes nearly half of the working day to
hospitalized patients, and a disproportionate amount
of this time is spent in intensive care units. The most
common reasons for the appearance of kidney specialists in intensive care units include AKI, particularly in
septic patients, hypertension, electrolyte and acid-base
disturbances, and patients with ESRD and a host of
distressing conditions, including hemorrhage, cardiac
failure, myocardial ischemia, pulmonary edema, postsurgical recovery, and infection-related problems. As
such, nephrologists must become facile with the tools
of intensivists, whose numbers now include experts in
infectious disease, neurology, surgery, anesthesiology,
and emergency medicine. Moreover, nephrologists
must collaborate with intensivists to provide cohesive
and coherent care plans because critically ill patients
cannot be treated in isolation, as a multitude of other
factors impinge on their health.

Sepsis is the most common cause of AKI and AKI is
a harbinger of sepsis.3 Therefore, recognition of sepsis
is paramount followed by its treatment with antibiotics.
An accrual of knowledge about newer antibiotics and
their respective dosing regimens, especially those reserved for more exotic infections and those that are
intrinsically nephrotoxic, must be achieved firsthand. In
addition, systematic avoidance of nephrotoxic antibiotics
must be practiced, since such nephrotoxins may prove
injurious when combined with other injurious renal
exposures, such as radiocontrast media. Protocolized
avoidance of nephrotoxins, especially iodinated radiocontrast media, requires collaborative leadership and
input from nephrologists at pharmacy therapeutics committees. This knowledge must be judiciously distributed
among other involved health care personnel, pharmacists, and the electronic health record, with fault-free dispersal through computerized order entry systems, given
the emerging specter of stage 2 meaningful use criteria
that begin in 2013.4 These criteria encourage information
technology in health care as a driver of continuous quality improvement at the point of care and information
exchange in a highly structured format.
AKI runs rampant in intensive care units and has multiple and often overlapping causes. AKI is frequently
complicated by a reduction of uremic solute clearance
and/or urine output to the extent that renal replacement
therapy is necessary. The intensivist-nephrologist must
now be conversant in continuous renal replacement
therapies because intermittent hemodialysis may not
be feasible in hypotensive individuals, especially those
who become vasopressor-dependent for several days or
more. Whether using continuous venovenous therapy
as purely hemofiltration or as hemodiafiltration, the
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critical care kidney specialist must appreciate not only
the positive aspects of continuous therapy but also the
negative ones, including net negative potassium and
phosphorus balance,5 as well as reductions in vasopressor concentrations and antibiotic concentrations. With regard to the latter, continuous venovenous therapy may
offer the intensive care pharmacy an easier pathway to
effective antibiotic dosing,6 compared with intermittent
dialysis or sustained low-efficiency dialysis, unless the
latter modality is on a continuous basis as is possible
with regional citrate anticoagulation.7 Recently, sustained low-efficiency dialysis/regional citrate anticoagulation has been proved effective and safe in individuals
with severely compromised hepatic function. Furthermore, patients with portal-systemic encephalopathy or
cerebral edema from other causes who are at risk for impending cerebral herniation may benefit from continuous therapies.
The effective circulatory volume can be manipulated,
as can the prevailing tonicity in which the swollen brain
is bathed. The manipulation of serum sodium with renal
replacement therapy8 may now supplant or augment
conventional osmotherapy9 and is now within the purview of the nephrologist-intensivist who may now be
called upon to enact treatments for brain shrinkage.
Likely, consultations requesting these treatments will increase. Even if armed with more advanced techniques of
renal replacement therapy, the nephrologist-intensivist
must now acknowledge that the determination of ‘‘volume status’’ is ever more difficult in desperately ill individuals. Protocolized volume resuscitation algorithms
have proved worthy but sometimes at a cost.10
Volume or fluid overload has become the rule rather
than the exception. The nephrologist must exercise judgment jealously on behalf of the patient because fluid
overload is associated with worse outcomes, including
increased intubation and ventilator times, suboptimal
recovery from AKI, and mortality.11 However, this judgment must be annealed to more modern and sophisticated techniques of volume assessment, such as inferior
vena cava ultrasonography that demonstrates luminal
obliteration, central venous pressure monitoring in selected cases, and dynamic measurements of stroke volume changes during mechanical ventilation that use
Doppler ultrasonography, pulse contour analysis, and
bioreactance measurements.12 These data, in combination with traditional measures of perfusion (vital signs,
arterial blood gas and lactate measurements) may prove
more informative than clinical ‘‘guesstimation.’’ Finally,
a simple maneuver such as the assessment of fluid responsiveness to passive leg raising may prove rapidly
and clinically useful.13 Unlike the aforementioned
methods, this subtle and sublime technique is also exceedingly inexpensive.
Recognition of when fluid overload has occurred is
a minimal requirement, but preventing it is better. Preven-

tion requires not only an assessment of fluid inputs and
outputs but also much more careful analysis: the calculus
of mass balance and electrolyte–free water determination,
with appropriate forecasting.14,15 Notably, no large scale,
commercially available electronic health care record
carries out these calculations in a truly meaningful
fashion that amplifies care of the patient. All account for
fluid inputs and outputs, colloids, and blood products
as equivalents, and 10 L of 5% dextrose in water is
ranked equally with 10 L of 0.9 saline solution. Ionic
compositions are systematically ignored, especially
with regard to enteral and parenteral nutrition solutions,
with brutal consequences for patients. Patients may be
overly ultrafiltered by nephrologists who fail to perform
such mass balance. Conversely, intensivists who ignore
mass balance may induce dysnatremias with or without
fluid overload. Lastly, simple clinical acuity cannot
be forsaken. Otherwise, differentiation of AKI from an
abdominal compartment syndrome16 with elevated bladder pressure, right-sided heart failure, or hepatic sinusoidal hypertension will not occur.
Certainly, the nephrologist’s scope of business has
been forcefully expanded in conjunction with the enlarging critical care space. This has provoked the evolution of
a new brand of nephrology and nephrologist. This discipline, "newphrology," welcomes and actively engages the
nephrologist as an intensive care kidney specialist. These
individuals will increase in number and take their place
among those nephrologists who became disciples of
other former ‘‘new’’ disciplines of nephrology, including
kidney transplantation and interventional nephrologists.
These "newphrologists" are favorably positioned to participate in and impact patient care and research in medical, surgical, neurosurgical, and pediatric intensive care
units. These individuals will be dedicated to breaking
the wave of AKI through the earlier recognition, mitigation of aggravating factors, and treatment of AKI—the
selfsame mantra of nephrologists who treat CKD. In
fact, they are already doing so as delineated by the series
of articles in this issue of Advances in Chronic Kidney Disease, as collated by our Guest Editor, Kathleen Liu, herself
a nephrologist-intensivist.
Jerry Yee, MD
Editor-in-Chief
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